StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
Condition: Skin Wound; Burns; Trauma-related Wound
MeSH terms: Wounds and Injuries
Intervention: StrataGraft Skin Tissue
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 30.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: No

Summary:

      The proposed study is designed as a phase Ib open-label, dose-escalation, multicenter study
      evaluating the safety, tolerability, and efficacy of StrataGraft skin tissue in promoting the
      healing of the deep partial-thickness component of complex skin defects. The proposed study
      population will include patients with 3-49% Total Body Surface Area (TBSA) complex skin
      defects including a deep partial-thickness component resulting from thermal injury. The study
      has been designed to focus on the evaluation of safety and tolerability of prolonged exposure
      to increasing amounts of a single application of StrataGraft skin tissue, while also
      assessing the potential for StrataGraft tissue to promote healing of the deep
      partial-thickness component of these complex skin defects as an alternative to donor site
      harvesting and autografting. Targeted enrollment for this study is up to 30 patients with
      complex skin defects due to thermal burns which require surgical excision and autografting.
      Subjects will be sequentially enrolled in two cohorts of increasing treatment area receiving
      StrataGraft skin tissue that has been stored refrigerated prior to clinical use. A third
      cohort will receive StrataGraft skin tissue which has been stored cryopreserved and thawed in
      the operating room just prior to grafting.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Men and women aged 18-65 years, inclusive

          -  Written informed consent

          -  Sufficient healthy skin identified and designated as a donor site in the event that
             the StrataGraft treatment site requires autografting

          -  Complex skin defects of 3-49% TBSA requiring excision and autografting

          -  Total burn may consist of more than one wound area

          -  Deep partial-thickness thermal burn(s) with total area of 88 to 880 cm2 requiring
             excision and autografting

          -  First excision and grafting of treatment sites

        Exclusion Criteria:

          -  Pregnant women and prisoners

          -  Patients receiving systemic immunosuppressive therapy

          -  Patients with a known history of malignancy

          -  Preadmission insulin-dependent diabetic patients

          -  Patients with concurrent conditions that in the opinion of the investigator may
             compromise patient safety or study objectives

          -  Expected survival of less than three months

          -  Participation in the treatment group of an interventional study within preceding 90
             days prior to enrollment

          -  Full-thickness burns will be excluded as treatment sites

          -  Chronic wounds will be excluded as treatment sites

          -  The face, head, neck, hands, feet, buttocks, and areas over joints will be excluded as
             treatment sites

          -  Treatment sites adjacent to unexcised eschar

          -  Clinical suspicion of burn wound infection at the anticipated treatment sites